Abstract: Neuroactive steroid anaesthetic agents, methods for their preparation and compositions comprising the same are disclosed. Also provided are scaled up and/or GMP methods for preparing neuroactive steroids, such as alfaxalone, alfadolone and alfadolone acetate.

Abstract: Neuroactive steroid anaesthetic agents, methods for their preparation and compositions comprising the same are disclosed. Also provided are scaled up and/or GMP methods for preparing neuroactive steroids, such as alfaxalone, alfadolone and alfadolone acetate.

Abstract: A novel process for making estra-4,9(10)-diene-3,17-dione steroids from readily available 19-nor-androst-4-ene-3-one steroids by a straightforward three-step process. Products of this process are important intermediates in the preparation of biologically active substances.

Abstract: A novel process for making estra-4,9(10)-diene-3,17-dione steroids from readily available 19-nor-androst-4-ene-3-one steroids by a straightforward three-step process. Products of this process are important intermediates in the preparation of biologically active substances.

Abstract: A novel process for making estra-4,9(10)-diene-3,17-dione steroids from readily available 19-nor-androst-4-ene-3-one steroids by a straightforward three-step process. Products of this process are important intermediates in the preparation of biologically active substances.

Abstract: Disclosed is a 20,21-dihalo steroid (VII) and a steroidal sulfoxide (VIII) as well as processes to produce them. The 20,21-dihalo steroid (VII) and sulfoxide (VIII) are intermediates useful in the preparation of pharmaceutically useful corticoids.

Abstract: The present invention is a process for the transformation of a 17-keto steroid (II) to a corticoid (XI) which has pharmaceutical utility.

Abstract: A process for the preparation of corticoids (XI) which comprises reacting a protected 17-keto steroid (II) with a metallated 1,2-dihaloethene (III).

Abstract: A process for the preparation of corticoids (XI) which comprises reacting a protected 17-keto steroid (II) with a metallated 1,2-dihaloethene (III).

Abstract: A process for the preparation of corticoids (XI) which comprises reacting a protected 17-keto steroid (II) with a metallated 1,2-dihaloethene (III).

Abstract: This invention relates to processes for base catalyzed acylations using enol esters, for example, isopropenyl acetate. Particularly, the processes are useful for acylating acid sensitive alcohols including hydroxy steroids.

Abstract: A rapid and efficient process for preparing the useful antibiotic erythromycin ethyl succinate in high yield which comprises reacting erythromycin USP quality free base with ethyl succinyl chloride in a two phase system consisting of an organic solvent which is capable of forming two phases with water or an aqueous base, and an aqueous base.

Abstract: 17-Keto steroids (I) in their protected form (IIa or IIb) are reacted with a metalated olefin (VI) to give a 21-aldehyde (IV) which is readily transformed to a 16-unsaturated pregnane (V) which is useful in the production of commercially important substituted corticoids.

Abstract: A new method for preparing cytosine arabinoside involving the cyanovinylation of the aminooxazoline of D-arabinose by cis-.beta.-[trimethylammonium]-acrylonitrile tosylate. Also included are new preparations of the aminooxazoline of D-arabinose and the anion of cis-1-cyano-2-hydroxyethylene.

Abstract: A new method for preparing cytosine arabinoside involving the cyanovinylation of the aminooxazoline of D-arabinose by cis-.beta.-[trimethylammonium]-acrylonitrile tosylate. Also included are new preparations of the aminooxazoline of D-arabinose and the anion of cis-1-cyano-2-hydroxyethylene.

Abstract: A new method for preparing cytosine arabinoside involving the cyanovinylation of the aminooxazoline of D-arabinose by cis-.beta.-[trimethylammonium]-acrylonitrile tosylate. Also included are new preparations of the aminooxazoline of D-arabinose and the anion of cis-1-cyano-2-hydroxyethylene.DESCRIPTION OF THE PRIOR ARTCytosine arabinoside, an anti-leukemic agent also known as 1-.beta.-D-arabinofuranosylcytosine, is a known anti-leukemic agent. Consequently, an economical and safe synthesis of the compound and other significant cytosine nucleosides is an important contribution to the well being of the populace. The Orgel and Sanchez patent, U.S. Pat. No. 3,658,788, provided a new way of preparing cytosine nucleosides, particularly cytosine arabinoside. The process consisted of preparing an aminooxazoline intermediate which is then cyanovinylated to a cyclocytidine salt. The cyclocytidine salt is then treated with aqueous ammonia to form the cytosine nucleoside.